SELLAS Life Sciences Group (SELLAS Life Sciences Group) EBIT per Share : $-1.39 (TTM As of Dec. 2023)

View and export this data going back to 2008. Start your Free Trial

What is SELLAS Life Sciences Group EBIT per Share?

SELLAS Life Sciences Group's EBIT per Share for the three months ended in Dec. 2023 was $-0.27. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.39.

During the past 3 years, the average EBIT per Share Growth Rate was 13.80% per year. During the past 5 years, the average EBIT per Share Growth Rate was 51.40% per year. During the past 10 years, the average EBIT per Share Growth Rate was 66.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for SELLAS Life Sciences Group's EBIT per Share or its related term are showing as below:

SLS' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: 4.2 Med: 37.4 Max: 83.2
Current: 13.8

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of SELLAS Life Sciences Group was 83.20% per year. The lowest was 4.20% per year. And the median was 37.40% per year.

SLS's 3-Year EBIT Growth Rate is ranked better than
63.54% of 1311 companies
in the Biotechnology industry
Industry Median: 3.6 vs SLS: 13.80

SELLAS Life Sciences Group's EBIT for the three months ended in Dec. 2023 was $-8.18 Mil.

SELLAS Life Sciences Group EBIT per Share Historical Data

The historical data trend for SELLAS Life Sciences Group's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SELLAS Life Sciences Group EBIT per Share Chart

SELLAS Life Sciences Group Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

-6.73

-2.13

-1.27

-1.65

-1.36

SELLAS Life Sciences Group Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EBIT per Share	Get a 7-Day Free Trial															0.03	-0.48	-0.32	-0.33	-0.27

SELLAS Life Sciences Group EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

SELLAS Life Sciences Group's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-37.869	/	27.777
=	-1.36

SELLAS Life Sciences Group's EBIT per Share for the quarter that ended in Dec. 2023 is calculated as

	EBIT per Share		(Q: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-8.177	/	30.805
=	-0.27

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.39

SELLAS Life Sciences Group (NAS:SLS) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

SELLAS Life Sciences Group EBIT per Share Related Terms

Thank you for viewing the detailed overview of SELLAS Life Sciences Group's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

SELLAS Life Sciences Group (SELLAS Life Sciences Group) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SELLAS Life Sciences Group Inc (NAS:SLS) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

RXK3:Germany

Address

7 Times Square, Suite 2503, New York, NY, USA, 10036

Website

https://www.sellaslifesciences.com

SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.

Executives

Angelos M. Stergiou	director, officer: President and CEO	C/O SELLAS LIFE SCIENCES GROUP, INC., 2000 CROW CANYON PLACE, SUITE 380, SAN RAMON CA 94583
Barbara A Wood	officer: EVP, Gen. Counsel, Corp. Sec.	58 S SERVICE RD, MELVILLE NY 11747
John Thomas Burns	officer: VP, Finance & Corp Controller	16760 SW UPPER BOONES FERRY RD, SUITE 101, PORTLAND X1 97224
Katherine Bach Kalin	director	3201 CARNEGIE AVENUE, CLEVELAND OH 44115
Robert Francomano	officer: Chief Commercial Officer	C/O STEMLINE THERAPEUTICS, INC., 750 LEXINGTON AVENUE, 11TH FLOOR, NEW YORK NY 10022
Nicholas J. Sarlis	officer: Chief Medical Officer and SVP	C/O SELLAS LIFE SCIENCES GROUP, INC., 2000 CROW CANYON PLACE, STE. 380, SAN RAMON CA 94583
Stephen F Ghiglieri	director	C/O NEUROGESX INC., 981 INDUSTRIAL ROAD SUITE F, SAN CARLOS CA 94070
Jane Wasman	director	C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
David A Scheinberg	director	325 CENTRAL PARK W, APT 38, NEW YORK NY 10025
Van Nostrand Robert L	director	C/O ACHILLION PHARMACEUTICALS, INC., 300 GEORGE STREET, NEW HAVEN CT 06511
John Varian	director	ARYX THERAPEUTICS,INC., 6300 DUMBARTON CIRCLE, FREMONT CA 94555
Eqc Private Markets Sac Fund Ltd-eqc Biotech Sely Ii Fund`	10 percent owner	C/O EQUILIBRIA CAPITAL MANAGEMENT LTD., ONE BERMUDIANA ROAD, HAMILTON D0 HM08
Eqc Private Markets Sac Fund Ltd-eqc Biotech Sely I Fund	10 percent owner	C/O EQUILIBRIA CAPITAL MANAGEMENT LTD., ONE BERMUDIANA ROAD, HAMILTON D0 HM08
Equilibria Capital Management Ltd	10 percent owner	O'HARA HOUSE, ONE BERMUDIANA ROAD, HAMILTON D0 HM08
Eqc Private Markets Ii Sac Fund Ltd-eqc Biotech Sely Iii Fund	10 percent owner	C/O EQUILIBRIA CAPITAL MANAGEMENT LTD., ONE BERMUDIANA ROAD, HAMILTON D0 HM08